Company intelligence / Profile preview
Arcadia Medicine
Unknown/information not providedarcadiamedicine.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Arcadia Medicine has developed a pipeline of next-generation psychoactive therapeutics targeting mental health disorders. Their lead candidates are engineered to improve safety and efficacy over existing empathogen-based therapies, with preclinical and early clinical development underway for GAD, MDD, and SUD. No published clinical results yet; programs are in or approaching first-in-human studies.[1]
- Therapeutic areas
- Psychiatry
- Modalities
- Psychoactive empathogensEngineered MDMA analogs
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Arcadia Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arcadia Medicine.